BMI eligibility at a glance
Check your BMI
Enter your height and weight to see your number, and whether you would likely meet the standard criteria. This is a guide only. A doctor makes the final decision.
BMI Calculator
Standard FDA eligibility criteria
BMI ≥ 30
Classified as obesity. Eligible for all FDA-approved weight loss medications, whether or not other health conditions are present.
BMI ≥ 27 with at least one qualifying condition
Source: FDA approved indications + WHO GLP-1 guideline 2024 [1]
Reasons your doctor might say no
Medullary thyroid carcinoma (MTC)
Affects: All GLP-1 class drugs
Personal or family history of this rare thyroid cancer. The FDA requires a serious warning on the label because animal studies showed a thyroid tumour risk with GLP-1 drugs.
MEN 2 syndrome
Affects: All GLP-1 class drugs
Multiple Endocrine Neoplasia type 2. It is an inherited condition that makes thyroid and other hormone-related tumours more likely.
Pregnancy
Affects: Phentermine/topiramate (black box) and GLP-1s (not studied)
Phentermine/topiramate causes birth defects, so it cannot be used. GLP-1s are not approved for pregnancy.
Active opioid use
Affects: Naltrexone/bupropion (Contrave)
Naltrexone blocks how opioids work in your body. Taking it while on opioids causes immediate withdrawal.
History of seizures
Affects: Naltrexone/bupropion
Bupropion makes seizures more likely — not suitable for people with a seizure history.
Glaucoma or overactive thyroid
Affects: Phentermine/topiramate
Phentermine is a stimulant, so it is not suitable in narrow-angle glaucoma or an overactive thyroid.
BMI isn't perfect
- Does not tell fat from muscle. A very muscular person may be above the cut-off without much body fat
- Some Asian populations face risk to their metabolic health at lower BMI levels (some guidelines use ≥25 or ≥27)
- Does not capture where fat is stored. Belly fat carries more health risk than fat elsewhere
Think you might qualify? Next step: talk to your doctor
Find out what to bring to the appointment, how to open the conversation, and what to do if your GP does not know the current treatments.
How to talk to your doctor →Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
FDA eligibility criteria sources
BMI cut-offs of ≥30 (or ≥27 with qualifying conditions) come from the FDA-approved uses of semaglutide, tirzepatide, orforglipron, liraglutide, phentermine-topiramate, naltrexone-bupropion, and orlistat. The WHO GLP-1 guideline 2024 summarises current prescribing criteria across jurisdictions.
- STEP 1 — Semaglutide (injection): 1,961 adults with obesity or overweight with comorbidities, no type 2 diabetes, 68 weeks. New England Journal of Medicine, 2021. View source ↗
- SURMOUNT-1 — Tirzepatide: 2,539 adults with obesity or overweight with comorbidities, no type 2 diabetes, 72 weeks. New England Journal of Medicine, 2022. View source ↗
- ATTAIN-1 — Orforglipron: 3,127 adults with obesity or overweight with comorbidities, no type 2 diabetes, 72 weeks. New England Journal of Medicine, 2025. View source ↗
- SCALE Obesity and Prediabetes — Liraglutide: 3,731 adults with obesity or overweight with comorbidities, 56 weeks. New England Journal of Medicine, 2015. View source ↗
- CONQUER — Phentermine / Topiramate: 2,487 adults with obesity and at least 2 weight-related health conditions, 56 weeks. The Lancet, 2011. View source ↗
- COR-I — Naltrexone / Bupropion: 1,742 adults with obesity or overweight with comorbidities, 56 weeks. The Lancet, 2010. View source ↗
- XENDOS — Orlistat: 3,305 adults with obesity, including those with prediabetes, 4 years (208 weeks). Diabetes Care, 2004. View source ↗
- WHO guideline on GLP-1 receptor agonists for obesity (2024) — prescribing criteria across jurisdictions View source ↗
What if you do not meet these criteria?
Not qualifying for medication does not mean you are out of options. Lifestyle approaches work for everyone, and they are the foundation of managing weight over the long term.
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: